Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) delivers innovative drug delivery solutions through its proprietary ENHANZE® technology, transforming subcutaneous administration of biologics. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, strategic partnerships, and regulatory milestones.
Access timely press releases covering earnings reports, ENHANZE® licensing agreements, and oncology pipeline advancements. Our curated collection features updates on FDA submissions, collaboration expansions with global pharmaceutical leaders, and technology applications across autoimmune disorders and cancer treatments.
Key updates include partnership announcements with industry leaders, clinical trial progress for subcutaneous therapies, and financial performance insights. The resource serves investors tracking royalty revenue models and analysts monitoring competitive positioning in biopharmaceutical delivery systems.
Bookmark this page for direct access to verified corporate communications and objective reporting on Halozyme's mission to enhance treatment experiences through advanced drug delivery platforms. Regularly updated to reflect the company's latest achievements in patient-centric biotechnology innovation.
Halozyme Therapeutics (NASDAQ: HALO) announced presentations of collaborative studies utilizing ENHANZE® technology at the 2021 ASCO Annual Meeting from June 4-8. Key studies included Phase 3 results for AL amyloidosis treatment and preliminary analyses of nivolumab. Highlights also featured cost analysis for a fixed-dose combination treatment for HER2-positive breast cancer. Halozyme's ENHANZE® technology aims to enhance patient treatment experiences, and the company has licensed this technology to major pharmaceutical firms. The press release emphasizes ongoing development and collaboration, impacting potential revenue through milestones and royalties.
Halozyme Therapeutics (NASDAQ: HALO) announced its participation in two upcoming virtual investor conferences. The first is the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, featuring Dr. Helen Torley at 11:20 a.m. ET. The second is the JMP Securities Life Sciences Conference on June 17, 2021, with Elaine Sun at 3:00 p.m. ET. Live webcasts will be available on their website, along with archived recordings for a month after each event.
Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen received positive opinions from the EMA's CHMP for expanding DARZALEX® (daratumumab) subcutaneous formulation to treat AL amyloidosis and relapsed multiple myeloma. The first opinion supports the use of DARZALEX® with cyclophosphamide, bortezomib, and dexamethasone for newly diagnosed AL amyloidosis patients. The second opinion recommends its use with pomalidomide and dexamethasone for specific multiple myeloma patients. These recommendations will be reviewed by the European Commission for final approval.
Halozyme Therapeutics (NASDAQ: HALO) reported strong Q1 2021 results with revenues of $89 million, a 250% increase from $25.4 million in Q1 2020. Key drivers included $30 million in milestone revenues from Janssen and Bristol Myers Squibb, and a 119% rise in royalty revenue from subcutaneous DARZALEX®. Operating income reached $50.7 million compared to a loss of $3.2 million a year earlier. The company expects 2021 revenues between $375 million and $395 million, reflecting 40%-48% growth. Cash and equivalents totaled $764.3 million at quarter-end.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that CEO Dr. Helen Torley will present virtually at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 12:30 p.m. ET. Investors can access the presentation via the Halozyme website, and a recording will be available for six months post-event. Halozyme is known for its innovative ENHANZE technology, which enhances drug delivery and has positively impacted over 400,000 patients worldwide through collaborations with major pharmaceutical companies.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will host a webcast for its Q1 2021 financial results on May 10 at 4:30 p.m. ET. CEO Dr. Helen Torley will lead the call, releasing results for the quarter ended March 31, 2021 following market close. The call will be accessible via the Investors section of Halozyme’s corporate website, with registration open until the call starts. Halozyme is known for its innovative ENHANZE® technology, which enhances patient experiences by reducing treatment times for injectable therapies.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced the pricing of a $700 million private offering of convertible senior notes due 2027. The notes will carry a 0.25% annual interest rate and can convert to cash or shares at an initial conversion price of $77.17 per share. The total net proceeds are estimated at $681.9 million, allocated primarily for repurchasing existing convertible notes and shares, as well as general corporate purposes. The offering is expected to close on March 1, 2021.
Halozyme Therapeutics announced a proposed offering of $500 million in convertible senior notes due 2027, subject to market conditions. The notes will be sold to qualified institutional buyers under Rule 144A of the Securities Act. The company may grant a 30-day option for an additional $75 million of notes. Proceeds will be used for repurchasing existing notes and common stock, enhancing shareholder value. The convertible notes will accrue interest and have specific terms for conversion starting from September 1, 2026. This offering could impact the market price of Halozyme's common stock.
Halozyme Therapeutics (NASDAQ: HALO) reported robust financial results for Q4 and the full year 2020, showcasing a transition to profitability. Q4 revenue soared to $121.7 million, a substantial increase from $53.7 million in Q4 2019, driven by new product approvals and increased royalties. The company projects 2021 revenues of $375-$395 million, marking 40%-48% growth year-over-year. Operating income is expected to grow by 49%-63%. Additionally, Halozyme plans to repurchase up to $125 million in common stock. Cash reserves stood at $368 million.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to host a webcast for its fourth-quarter 2020 financial results on February 23, 2021, at 4:30 p.m. ET. The call, led by CEO Dr. Helen Torley, follows the release of financial results for the quarter ending December 31, 2020. Interested parties can register for the call via the provided link, with a recording available post-event. Halozyme specializes in enhancing patient treatment experiences through its innovative ENHANZE® technology, which shortens drug administration times, and collaborates with various pharmaceutical companies to further develop this technology.